- Conditions
- Active Noninfectious Uveitis Affecting the Posterior Segment
- Interventions
- REGN7041
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 5
- States / cities
- Sacramento, California • Oak Park, Illinois • Nashville, Tennessee + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–10
of 10
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Uveitis, Macular Edema, Uveitis, Posterior, Uveitis, Anterior, Panuveitis, Uveitis, Intermediate
- Interventions
- 4 mg CLS-TA, 0.8 mg CLS-TA
- Drug
- Lead sponsor
- Clearside Biomedical, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 11
- States / cities
- Miami, Florida • Atlanta, Georgia • Chicago, Illinois + 8 more
- Conditions
- Macular Edema
- Interventions
- Updated DEX PS DDS Applicator, Approved DEX PS DDS Applicator, Dexamethasone
- Device · Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 7
- States / cities
- Glendale, California • North Dartmouth, Massachusetts • Independence, Missouri + 4 more
- Conditions
- Noninfectious Posterior Uveitis
- Interventions
- fluocinolone acetonide intravitreal implant, Fluocinolone acetonide 2.1mg
- Drug
- Lead sponsor
- Bausch & Lomb Incorporated
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 278 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2005
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Noninfectious Uveitis
- Interventions
- LX211
- Drug
- Lead sponsor
- Lux Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 155 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 28
- States / cities
- Peoria, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 24 more
- Conditions
- Non-infectious Uveitis
- Interventions
- AIN457, AIN 457
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 20
- States / cities
- Beverly Hills, California • Los Angeles, California • Sacramento, California + 16 more
- Conditions
- Uveitis, Posterior, Uveitis, Intermediate
- Interventions
- V404
- Drug
- Lead sponsor
- Forsight Vision4
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 5
- States / cities
- Golden, Colorado • Atlanta, Georgia • Omaha, Nebraska + 2 more
- Conditions
- Uveitis, Posterior, Uveitis, Intermediate, Panuveitis
- Interventions
- Acthar Gel
- Drug
- Lead sponsor
- Mallinckrodt
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 8
- States / cities
- Clearwater, Florida • Indianapolis, Indiana • Waltham, Massachusetts + 5 more
- Conditions
- Uveitis Posterior Non-Infectious, Uveitis, Intermediate, Noninfectious Panuveitis
- Interventions
- ESK-001
- Drug
- Lead sponsor
- Alumis Inc
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 17
- States / cities
- Beverly Hills, California • Los Angeles, California • Palo Alto, California + 12 more
- Conditions
- Uveitis, Intermediate Uveitis, Posterior Uveitis, Panuveitis, Noninfectious Uveitis
- Interventions
- triamcinolone acetonide (Triesence®)
- Drug
- Lead sponsor
- Clearside Biomedical, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Omaha, Nebraska • Cleveland, Ohio